Search

Your search keyword '"Helm-Petersen S"' showing total 5 results
Start Over Author "Helm-Petersen S"
5 results on '"Helm-Petersen S"'

2. Drug response prediction in high-risk multiple myeloma

Author

Vangsted, A. J., Helm-Petersen, S., Cowland, J. B., Jensen, P. B., Gimsing, P., Barlogie, B., Knudsen, S., Vangsted, A. J., Helm-Petersen, S., Cowland, J. B., Jensen, P. B., Gimsing, P., Barlogie, B., and Knudsen, S.

Abstract

A Drug Response Prediction (DRP) score was developed based on gene expression profiling (GEP) from cell lines and tumor samples. Twenty percent of high-risk patients by GEP70 treated in Total Therapy 2 and 3A have a progression-free survival (PFS) of more than 10 years. We used available GEP data from high-risk patients by GEP70 at diagnosis from Total Therapy 2 and 3A to predict the response by the DRP score of drugs used in the treatment of myeloma patients. The DRP score stratified patients further. High-risk myeloma with a predicted sensitivity to melphalan by the DRP score had a prolonged PFS, HR = 2.4 (1.2–4.9, P = 0.014) and those with predicted sensitivity to bortezomib had a HR 5.7 (1.2–27, P = 0.027). In case of predicted sensitivity to bortezomib, a better response to treatment was found (P = 0.022). This method may provide us with a tool for identifying candidates for effective personalized medicine and spare potential non-responders from suffering toxicity.

Published
2018

3. Early relapsed disease of multiple myeloma following up-front HDM-ASCT: a study based on the Danish Multiple Myeloma Registry in the period 2005 to 2014.

Author

Helm-Petersen S, Sørrig R, Klausen TW, Preiss B, Frølund UC, Helleberg C, Breinholt M, Andersen MK, Abildgaard N, Gimsing P, and Vangsted AJ

Subjects
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Denmark epidemiology, Female, Hematopoietic Stem Cell Transplantation, History, 21st Century, Humans, Immunologic Factors administration & dosage, Male, Middle Aged, Multiple Myeloma history, Multiple Myeloma pathology, Multiple Myeloma therapy, Population Surveillance, Prognosis, Proteasome Inhibitors administration & dosage, Recurrence, Registries, Transplantation, Autologous, Treatment Outcome, Multiple Myeloma epidemiology
Published
2018
Full Text
View/download PDF

4. Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population.

Author

Sørrig R, Klausen TW, Salomo M, Vangsted AJ, Frølund UC, Andersen KT, Klostergaard A, Helleberg C, Pedersen RS, Pedersen PT, Helm-Petersen S, Teodorescu EM, Preiss B, Abildgaard N, and Gimsing P

Subjects
Adult, Aged, Aged, 80 and over, Denmark, Female, Humans, Male, Middle Aged, Multiple Myeloma diagnosis, Prognosis, Agammaglobulinemia complications, Multiple Myeloma complications, Survival Analysis
Abstract

Immunoparesis (hypogammaglobulinemia) is associated to an unfavorable prognosis in newly diagnosed Multiple myeloma (MM) patients. However, this finding has not been validated in an unselected population-based cohort. We analyzed 2558 newly diagnosed MM patients in the Danish Multiple Myeloma Registry representing the entire MM population in Denmark from 2005-2013. Two-thousand two hundred and fifty three patients (90%) presented with reduction below lower normal levels of at least one uninvolved immunoglobulin. Using multivariable Cox regression we found that high age, high ISS score, high LDH and IgA MM were associated to both shorter overall survival and progression free survival. Furthermore, bone marrow plasma cell % was associated to short progression free survival. Immunoparesis had no independent significant effect on OS (HR 0.9 (95%CI: 0.7;1.0; p = 0.12)). Likewise, the number of suppressed immunoglobulins or the relative degree of suppressed uninvolved immunoglobulins from lower normal level (quantitative immunoparesis) was not associated to OS in the multivariable analysis. However, quantitative immunoparesis with at least 25% reduction (from lower normal level) of uninvolved immunoglobulins was associated to shorter PFS for the entire population. The impact of quantitative immunoparesis on PFS was present irrespective of calendar periods 2005-2008 and 2009-2013. Our population-based study does not confirm that immunoparesis at diagnosis is an independent prognostic factor regarding OS. However, quantitative immunoparesis is associated to a shorter PFS.

Published
2017
Full Text
View/download PDF

5. Causes of early death in multiple myeloma patients treated with high-dose therapy followed by autologous stem cell transplantation: A study based on the nationwide Danish Multiple Myeloma Registry.

Author

Thidemann Andersen K, Klausen T, Abildgaard N, Klarskov Andersen M, Frost Andersen N, Christian Frølund U, Helleberg C, Kjeldsen E, Pedersen P, Helm-Petersen S, Svirskaite A, Preiss B, Gimsing P, and Juul Vangsted A

Subjects
Adult, Aged, Autografts, Bortezomib administration & dosage, Cyclophosphamide administration & dosage, Denmark epidemiology, Dexamethasone administration & dosage, Disease-Free Survival, Female, Humans, Male, Middle Aged, Multiple Myeloma genetics, Multiple Myeloma metabolism, Survival Rate, Thalidomide administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Multiple Myeloma mortality, Multiple Myeloma therapy, Registries, Stem Cell Transplantation
Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results